Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Ipilimumab and its toxicities: a multidisciplinary approach.

Fecher LA, Agarwala SS, Hodi FS, Weber JS.

Oncologist. 2013 Jun;18(6):733-43. doi: 10.1634/theoncologist.2012-0483. Epub 2013 Jun 17. Review.

2.

Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.

Lens M, Testori A, Ferucci PF.

Curr Top Med Chem. 2012;12(1):61-6. Review.

PMID:
22196270
3.

Ipilimumab for patients with advanced mucosal melanoma.

Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.

Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28.

4.

Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.

Ascierto PA.

Tumori. 2013 Nov-Dec;99(6):302e-5e. doi: 10.1700/1390.15474.

PMID:
24503809
5.

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, Wolchok JD.

Ann Oncol. 2014 Nov;25(11):2277-84. doi: 10.1093/annonc/mdu441. Epub 2014 Sep 10.

6.

Management of immune-related adverse events and kinetics of response with ipilimumab.

Weber JS, Kähler KC, Hauschild A.

J Clin Oncol. 2012 Jul 20;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750. Epub 2012 May 21. Review.

PMID:
22614989
7.

Melanoma: more answers, more questions.

Urba WJ.

Oncologist. 2013 Jun;18(6):658-60. doi: 10.1634/theoncologist.2013-0212. No abstract available.

8.

Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.

Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D.

Semin Oncol. 2010 Oct;37(5):485-98. doi: 10.1053/j.seminoncol.2010.09.003. Review. Erratum in: Semin Oncol. 2012 Oct;39(5):625.

PMID:
21074064
9.

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.

Lipson EJ, Drake CG.

Clin Cancer Res. 2011 Nov 15;17(22):6958-62. doi: 10.1158/1078-0432.CCR-11-1595. Epub 2011 Sep 7. Review.

11.

Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.

Nallapaneni NN, Mourya R, Bhatt VR, Malhotra S, Ganti AK, Tendulkar KK.

J Natl Compr Canc Netw. 2014 Aug;12(8):1077-81.

PMID:
25099440
12.

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.

Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM.

PLoS One. 2013;8(1):e53745. doi: 10.1371/journal.pone.0053745. Epub 2013 Jan 14.

13.

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M.

Cancer Immunol Immunother. 2009 Aug;58(8):1297-306. doi: 10.1007/s00262-008-0642-y. Epub 2009 Jan 13.

PMID:
19139884
14.

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD.

Cancer. 2013 Oct 15;119(20):3687-95. doi: 10.1002/cncr.28282. Epub 2013 Aug 2.

15.

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.

Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ.

Ann N Y Acad Sci. 2013 Jul;1291:1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17. Review.

16.

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.

Camacho LH.

Cancer Med. 2015 May;4(5):661-72. doi: 10.1002/cam4.371. Epub 2015 Jan 25. Review.

17.

Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

Quirk SK, Shure AK, Agrawal DK.

Transl Res. 2015 Nov;166(5):412-24. doi: 10.1016/j.trsl.2015.06.005. Epub 2015 Jun 11. Review.

PMID:
26118951
18.

Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.

Danlos FX, Pagès C, Roux J, Jebali M, Gornet JM, Bagot M, Lebbé C.

Melanoma Res. 2015 Apr;25(2):178-9. doi: 10.1097/CMR.0000000000000132.

PMID:
25464388
19.

Ipilimumab (Yervoy) and the TGN1412 catastrophe.

Bakacs T, Mehrishi JN, Moss RW.

Immunobiology. 2012 Jun;217(6):583-9. doi: 10.1016/j.imbio.2011.07.005. Epub 2011 Jul 7. Review.

PMID:
21821307
20.

Immune checkpoint blockade.

Naidoo J, Page DB, Wolchok JD.

Hematol Oncol Clin North Am. 2014 Jun;28(3):585-600. doi: 10.1016/j.hoc.2014.02.002. Review.

PMID:
24880949
Items per page

Supplemental Content

Write to the Help Desk